{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:36Z","timestamp":1792788036504,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01DC020724"],"award-info":[{"award-number":["R01DC020724"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Remondi Foundation"},{"name":"Beraterlli Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vestibular schwannoma (VS) is an intracranial tumor arising from the Schwann cells of the vestibular nerve and is an important cause of sensorineural hearing loss (SNHL) in humans. The mechanisms underlying this SNHL are incompletely understood and currently, there are no drugs FDA approved specifically for VS. This knowledge gap significantly limits the development of effective treatments aimed at preventing, stabilizing, or reversing VS-induced SNHL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To identify effector molecules involved in VS-induced SNHL, we analyzed 47 immune-related factors secreted by tumor tissue in over 50 patients with sporadic VS and studied their correlation with preoperative hearing ability and tumor size. The most promising effector molecules were validated in vivo in an anatomically accurate mouse model of VS, and in vitro with mouse fibroblasts (L929) and auditory cell lines representing pro-sensory precursors of hair cells (UB-OC1) and auditory neuroblasts (US-VOT-N33).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We demonstrated that VS-induced SNHL was linked to increased secretion of TNF-\u03b1, IL-2R, CD163, eotaxin, and HGF, while larger tumor size was associated with higher levels of TNF-\u03b1, TNF-R2, IL-1\u03b1, IFN-\u03b1, MIP-1\u03b2, and IL-21 secretion. We identified heterogeneity among VS tumors in their capacity to secrete TNF-\u03b1. Tumors with high levels of TNF-\u03b1 secretion released cytokines and chemokines that significantly correlated with poor hearing (TWEAK and eotaxin) or better hearing (LIF, GRO-\u03b1, MIP-1\u03b1, MIP-3\u03b1, and IL-1\u03b1). Among these, TWEAK was notably abundant, with levels exceeding those in normal nerve tissue, elevated in patients with non-serviceable hearing and strongly linked to poor hearing in patients with TNF-\u03b1 high-secreting tumors. In vivo, we demonstrated that VS-secreted factors reach the inner ear, with elevated TNF-\u03b1 and TWEAK in the perilymph and blood of tumor-bearing mice with impaired hearing. In vitro, TWEAK amplified TNF-\u03b1 -mediated cytotoxicity in TNF-\u03b1 sensitive cells (L929) and auditory cell lines (UB-OC1 and US-VOT-N33) at tumor-secreted concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides compelling evidence that VS-secreted TNF-\u03b1 and TWEAK act synergistically to drive tumor-induced SNHL. Targeting the TNF-\u03b1\/TWEAK axis presents a promising new avenue for preventing VS-induced SNHL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-025-03364-z","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T11:26:25Z","timestamp":1739013985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immune profiling of human vestibular schwannoma secretions identifies TNF-\u03b1 and TWEAK as cytokines with synergistic potential to impair hearing"],"prefix":"10.1186","volume":"22","author":[{"given":"Sasa","family":"Vasilijic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Seist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina M.","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"3364_CR1","first-page":"347","volume":"36","author":"MS Mahaley Jr","year":"1990","unstructured":"Mahaley MS Jr., Mettlin C, Natarajan N, Laws ER Jr., Peace BB. Analysis of patterns of care of brain tumor patients in the United States: a study of the Brain Tumor section of the AANS and the CNS and the Commission on Cancer of the ACS. Clin Neurosurg. 1990;36:347\u201352.","journal-title":"Clin Neurosurg"},{"key":"3364_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/sni.sni_129_16","volume":"8","author":"A Harati","year":"2017","unstructured":"Harati A, Scheufler KM, Schultheiss R, et al. Clinical features, microsurgical treatment, and outcome of vestibular schwannoma with brainstem compression. Surg Neurol Int. 2017;8:45. https:\/\/doi.org\/10.4103\/sni.sni_129_16.","journal-title":"Surg Neurol Int"},{"issue":"6429","key":"3364_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/363515a0","volume":"363","author":"GA Rouleau","year":"1993","unstructured":"Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993;363(6429):515\u201321. https:\/\/doi.org\/10.1038\/363515a0.","journal-title":"Nature"},{"issue":"5","key":"3364_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-g","volume":"72","author":"JA Trofatter","year":"1993","unstructured":"Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;72(5):791\u2013800. https:\/\/doi.org\/10.1016\/0092-8674(93)90406-g.","journal-title":"Cell"},{"key":"3364_CR5","doi-asserted-by":"crossref","unstructured":"Moini J, Avgeropoulos NG, Samsam M. Chapter 10 - Schwannoma. In: Moini J, Avgeropoulos NG, Samsam M, editors. Epidemiology of brain and spinal tumors. Academic; 2021. pp. 179\u201396.","DOI":"10.1016\/B978-0-12-821736-8.00005-4"},{"issue":"11","key":"3364_CR6","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1007\/s00405-014-3317-7","volume":"272","author":"G Kontorinis","year":"2015","unstructured":"Kontorinis G, Nichani J, Freeman SR, et al. Progress of hearing loss in neurofibromatosis type 2: implications for future management. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German society for Oto-Rhino-Laryngology -. Head Neck Surg. 2015;272(11):3143\u201350. https:\/\/doi.org\/10.1007\/s00405-014-3317-7.","journal-title":"Head Neck Surg"},{"issue":"9","key":"3364_CR7","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","volume":"24","author":"SR Plotkin","year":"2022","unstructured":"Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Medicine: Official J Am Coll Med Genet. 2022;24(9):1967\u201377. https:\/\/doi.org\/10.1016\/j.gim.2022.05.007.","journal-title":"Genet Medicine: Official J Am Coll Med Genet"},{"issue":"2","key":"3364_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet Part A. 2010;152A(2):327\u201332. https:\/\/doi.org\/10.1002\/ajmg.a.33139.","journal-title":"Am J Med Genet Part A"},{"key":"3364_CR9","doi-asserted-by":"publisher","unstructured":"Reznitsky M, Petersen M, West N, Stangerup SE, Caye-Thomasen P. Epidemiology Of Vestibular Schwannomas - Prospective 40-Year Data From An Unselected National Cohort. Clinical epidemiology. 2019;11:981-6. https:\/\/doi.org\/10.2147\/CLEP.S218670.","DOI":"10.2147\/CLEP.S218670"},{"issue":"22","key":"3364_CR10","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1001\/jama.2013.5912","volume":"309","author":"DJ Genther","year":"2013","unstructured":"Genther DJ, Frick KD, Chen D, Betz J, Lin FR. Association of hearing loss with hospitalization and burden of disease in older adults. JAMA. 2013;309(22):2322\u20134. https:\/\/doi.org\/10.1001\/jama.2013.5912.","journal-title":"JAMA"},{"issue":"1","key":"3364_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006123-199701000-00001","volume":"40","author":"C Matthies","year":"1997","unstructured":"Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery. 1997;40(1):1\u20139. https:\/\/doi.org\/10.1097\/00006123-199701000-00001. discussion\u2013\u200910.","journal-title":"Neurosurgery"},{"issue":"1","key":"3364_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3892\/ol.2012.1011","volume":"5","author":"X Huang","year":"2013","unstructured":"Huang X, Xu J, Xu M, et al. Clinical features of intracranial vestibular schwannomas. Oncol Lett. 2013;5(1):57\u201362. https:\/\/doi.org\/10.3892\/ol.2012.1011.","journal-title":"Oncol Lett"},{"issue":"10","key":"3364_CR13","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1007\/s00701-023-05665-9","volume":"165","author":"R Fernandez-Mendez","year":"2023","unstructured":"Fernandez-Mendez R, Wan Y, Axon P, Joannides A. Incidence and presentation of vestibular schwannoma: a 3-year cohort registry study. Acta Neurochir. 2023;165(10):2903\u201311. https:\/\/doi.org\/10.1007\/s00701-023-05665-9.","journal-title":"Acta Neurochir"},{"issue":"3","key":"3364_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.otc.2023.02.013","volume":"56","author":"DB Welling","year":"2023","unstructured":"Welling DB. Targeted therapies in the treatment of vestibular Schwannomas: current state and New Horizons. Otolaryngol Clin North Am. 2023;56(3):543\u201356. https:\/\/doi.org\/10.1016\/j.otc.2023.02.013.","journal-title":"Otolaryngol Clin North Am"},{"issue":"3","key":"3364_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3171\/2012.9.jns12919","volume":"118","author":"ML Carlson","year":"2013","unstructured":"Carlson ML, Jacob JT, Pollock BE, et al. Long-term hearing outcomes following stereotactic radiosurgery for vestibular schwannoma: patterns of hearing loss and variables influencing audiometric decline. J Neurosurg. 2013;118(3):579\u201387. https:\/\/doi.org\/10.3171\/2012.9.jns12919.","journal-title":"J Neurosurg"},{"issue":"1","key":"3364_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3171\/2009.4.jns08895","volume":"112","author":"ME Sughrue","year":"2010","unstructured":"Sughrue ME, Yang I, Aranda D, et al. The natural history of untreated sporadic vestibular schwannomas: a comprehensive review of hearing outcomes. J Neurosurg. 2010;112(1):163\u20137. https:\/\/doi.org\/10.3171\/2009.4.jns08895.","journal-title":"J Neurosurg"},{"key":"3364_CR17","doi-asserted-by":"publisher","unstructured":"Daloiso A, Cazzador D, Concheri S, Tealdo G, Zanoletti E. Long-term hearing outcome for vestibular Schwannomas after Microsurgery and Radiotherapy: a systematic review and Meta-analysis. Otolaryngology\u2013head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck surgery. 2024. https:\/\/doi.org\/10.1002\/ohn.910","DOI":"10.1002\/ohn.910"},{"issue":"10","key":"3364_CR18","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1097\/mao.0000000000001560","volume":"38","author":"SF Ahsan","year":"2017","unstructured":"Ahsan SF, Huq F, Seidman M, Taylor A. Long-term hearing preservation after resection of vestibular Schwannoma: a systematic review and Meta-analysis. Otology & neurotology: official publication of the American Otological Society. Am Neurotology Soc [and] Eur Acad Otology Neurotology. 2017;38(10):1505\u201311. https:\/\/doi.org\/10.1097\/mao.0000000000001560.","journal-title":"Am Neurotology Soc [and] Eur Acad Otology Neurotology"},{"key":"3364_CR19","doi-asserted-by":"publisher","first-page":"687201","DOI":"10.3389\/fonc.2021.687201","volume":"11","author":"J Gan","year":"2021","unstructured":"Gan J, Zhang Y, Wu J, et al. Current understanding of hearing loss in sporadic vestibular schwannomas: a systematic review. Front Oncol. 2021;11:687201. https:\/\/doi.org\/10.3389\/fonc.2021.687201.","journal-title":"Front Oncol"},{"issue":"4","key":"3364_CR20","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/MLG.0b013e31803146c5","volume":"117","author":"HT Gouveris","year":"2007","unstructured":"Gouveris HT, Victor A, Mann WJ. Cochlear origin of early hearing loss in vestibular schwannoma. Laryngoscope. 2007;117(4):680\u20133. https:\/\/doi.org\/10.1097\/MLG.0b013e31803146c5.","journal-title":"Laryngoscope"},{"issue":"4","key":"3364_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/019459989411100404","volume":"111","author":"MP Widick","year":"1994","unstructured":"Widick MP, Telischi FF, Lonsbury-Martin BL, Stagner BB. Early effects of cerebellopontine angle compression on rabbit distortion-product otoacoustic emissions: a model for monitoring cochlear function during acoustic neuroma surgery. Otolaryngology\u2013head neck Surgery: Official J Am Acad Otolaryngology-Head Neck Surg. 1994;111(4):407\u201316. https:\/\/doi.org\/10.1177\/019459989411100404.","journal-title":"Otolaryngology\u2013head neck Surgery: Official J Am Acad Otolaryngology-Head Neck Surg"},{"issue":"3","key":"3364_CR22","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.3171\/2012.6.FOCUS12144","volume":"33","author":"JD Thakur","year":"2012","unstructured":"Thakur JD, Banerjee AD, Khan IS, et al. An update on unilateral sporadic small vestibular schwannoma. NeuroSurg Focus. 2012;33(3):E1. https:\/\/doi.org\/10.3171\/2012.6.FOCUS12144.","journal-title":"NeuroSurg Focus"},{"key":"3364_CR23","doi-asserted-by":"publisher","first-page":"18599","DOI":"10.1038\/srep18599","volume":"5","author":"S Dilwali","year":"2015","unstructured":"Dilwali S, Landegger LD, Soares VY, Deschler DG, Stankovic KM. Secreted factors from human vestibular Schwannomas can cause cochlear damage. Sci Rep. 2015;5:18599. https:\/\/doi.org\/10.1038\/srep18599.","journal-title":"Sci Rep"},{"issue":"3","key":"3364_CR24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3171\/2021.2.JNS203609","volume":"136","author":"J Gurewitz","year":"2022","unstructured":"Gurewitz J, Schnurman Z, Nakamura A, et al. Hearing loss and volumetric growth rate in untreated vestibular schwannoma. J Neurosurg. 2022;136(3):768\u201375. https:\/\/doi.org\/10.3171\/2021.2.JNS203609.","journal-title":"J Neurosurg"},{"key":"3364_CR25","doi-asserted-by":"publisher","first-page":"836504","DOI":"10.3389\/fonc.2022.836504","volume":"12","author":"A Brown","year":"2022","unstructured":"Brown A, Early S, Vasilijic S, Stankovic KM. Sporadic vestibular Schwannoma size and location do not correlate with the severity of hearing loss at initial presentation. Front Oncol. 2022;12:836504. https:\/\/doi.org\/10.3389\/fonc.2022.836504.","journal-title":"Front Oncol"},{"key":"3364_CR26","doi-asserted-by":"publisher","unstructured":"Wu L, Vasilijic S, Sun Y, et al. Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Sci Transl Med. 2021;13(602). https:\/\/doi.org\/10.1126\/scitranslmed.abd4816.","DOI":"10.1126\/scitranslmed.abd4816"},{"issue":"45","key":"3364_CR27","doi-asserted-by":"publisher","first-page":"eadf7295","DOI":"10.1126\/sciadv.adf7295","volume":"9","author":"S Vasilijic","year":"2023","unstructured":"Vasilijic S, Atai NA, Hyakusoku H, et al. Identification of immune-related candidate biomarkers in plasma of patients with sporadic vestibular schwannoma. Sci Adv. 2023;9(45):eadf7295. https:\/\/doi.org\/10.1126\/sciadv.adf7295.","journal-title":"Sci Adv"},{"issue":"1","key":"3364_CR28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41467-023-42762-w","volume":"15","author":"TF Barrett","year":"2024","unstructured":"Barrett TF, Patel B, Khan SM, et al. Single-cell multi-omic analysis of the vestibular schwannoma ecosystem uncovers a nerve injury-like state. Nat Commun. 2024;15(1):478. https:\/\/doi.org\/10.1038\/s41467-023-42762-w.","journal-title":"Nat Commun"},{"issue":"Suppl 5","key":"3364_CR29","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1002\/lary.31067","volume":"134","author":"KM Stankovic","year":"2024","unstructured":"Stankovic KM, Batts S, Welling DB, Vasilijic S. Immune Profiling of secreted factors from human vestibular Schwannoma cells and tumor-associated macrophages. Laryngoscope. 2024;134(Suppl 5):S1\u201314. https:\/\/doi.org\/10.1002\/lary.31067.","journal-title":"Laryngoscope"},{"key":"3364_CR30","doi-asserted-by":"publisher","first-page":"847157","DOI":"10.3389\/fcell.2022.847157","volume":"10","author":"A van Dieken","year":"2022","unstructured":"van Dieken A, Staecker H, Schmitt H, et al. Bioinformatic analysis of the Perilymph Proteome to generate a human protein atlas. Front cell Dev Biology. 2022;10:847157. https:\/\/doi.org\/10.3389\/fcell.2022.847157.","journal-title":"Front cell Dev Biology"},{"issue":"1","key":"3364_CR31","doi-asserted-by":"publisher","first-page":"14118","DOI":"10.1038\/s41598-024-64352-6","volume":"14","author":"J Edvardsson Rasmussen","year":"2024","unstructured":"Edvardsson Rasmussen J, Li P, Laurell G, Bergquist J, Eriksson PO. Hearing loss and its association with the proteome of perilymph, cerebrospinal fluid, and tumor tissue in patients with vestibular schwannoma. Sci Rep. 2024;14(1):14118. https:\/\/doi.org\/10.1038\/s41598-024-64352-6.","journal-title":"Sci Rep"},{"issue":"6","key":"3364_CR32","doi-asserted-by":"publisher","first-page":"e0198442","DOI":"10.1371\/journal.pone.0198442","volume":"13","author":"J Edvardsson Rasmussen","year":"2018","unstructured":"Edvardsson Rasmussen J, Laurell G, Rask-Andersen H, Bergquist J, Eriksson PO. The proteome of perilymph in patients with vestibular schwannoma. A possibility to identify biomarkers for tumor associated hearing loss? PLoS ONE. 2018;13(6):e0198442. https:\/\/doi.org\/10.1371\/journal.pone.0198442.","journal-title":"PLoS ONE"},{"key":"3364_CR33","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3389\/fneur.2020.00796","volume":"11","author":"S Early","year":"2020","unstructured":"Early S, Rinnooy Kan CE, Eggink M, Frijns JHM, Stankovic KM. Progression of Contralateral hearing loss in patients with sporadic vestibular Schwannoma. Front Neurol. 2020;11:796. https:\/\/doi.org\/10.3389\/fneur.2020.00796.","journal-title":"Front Neurol"},{"issue":"2","key":"3364_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1053\/j.seminoncol.2014.02.005","volume":"41","author":"W Al-Zoughbi","year":"2014","unstructured":"Al-Zoughbi W, Al-Zhoughbi W, Huang J, et al. Tumor macroenvironment and metabolism. Semin Oncol. 2014;41(2):281\u2013. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.02.005. \u200995.","journal-title":"Semin Oncol"},{"issue":"2","key":"3364_CR35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41596-018-0105-7","volume":"14","author":"J Chen","year":"2019","unstructured":"Chen J, Landegger LD, Sun Y, et al. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. Nat Protoc. 2019;14(2):541\u201355. https:\/\/doi.org\/10.1038\/s41596-018-0105-7.","journal-title":"Nat Protoc"},{"issue":"2","key":"3364_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nmeth.1177","volume":"5","author":"T Wurdinger","year":"2008","unstructured":"Wurdinger T, Badr C, Pike L, et al. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods. 2008;5(2):171\u20133. https:\/\/doi.org\/10.1038\/nmeth.1177.","journal-title":"Nat Methods"},{"issue":"11","key":"3364_CR37","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1038\/cddis.2011.111","volume":"2","author":"N Vanlangenakker","year":"2011","unstructured":"Vanlangenakker N, Bertrand MJ, Bogaert P, Vandenabeele P, Vanden Berghe T. TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members. Cell Death Dis. 2011;2(11):e230. https:\/\/doi.org\/10.1038\/cddis.2011.111.","journal-title":"Cell Death Dis"},{"issue":"7","key":"3364_CR38","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.18632\/oncotarget.14685","volume":"8","author":"A Roos","year":"2017","unstructured":"Roos A, Dhruv HD, Mathews IT, et al. Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells. Oncotarget. 2017;8(7):12234\u201346. https:\/\/doi.org\/10.18632\/oncotarget.14685.","journal-title":"Oncotarget"},{"issue":"8","key":"3364_CR39","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/cdd.2014.222","volume":"22","author":"CJ Kearney","year":"2015","unstructured":"Kearney CJ, Cullen SP, Tynan GA, et al. Necroptosis suppresses inflammation via termination of TNF- or LPS-induced cytokine and chemokine production. Cell Death Differ. 2015;22(8):1313\u201327. https:\/\/doi.org\/10.1038\/cdd.2014.222.","journal-title":"Cell Death Differ"},{"issue":"11","key":"3364_CR40","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41419-018-1137-1","volume":"9","author":"MA Anany","year":"2018","unstructured":"Anany MA, Kreckel J, Fullsack S, et al. Soluble TNF-like weak inducer of apoptosis (TWEAK) enhances poly(I:C)-induced RIPK1-mediated necroptosis. Cell Death Dis. 2018;9(11):1084. https:\/\/doi.org\/10.1038\/s41419-018-1137-1.","journal-title":"Cell Death Dis"},{"issue":"W1","key":"3364_CR41","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50(W1):W739\u201343. https:\/\/doi.org\/10.1093\/nar\/gkac382.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3364_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.1995.tb01618.x","volume":"54","author":"A Diez-Ruiz","year":"1995","unstructured":"Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol. 1995;54(1):1\u20138. https:\/\/doi.org\/10.1111\/j.1600-0609.1995.tb01618.x.","journal-title":"Eur J Haematol"},{"key":"3364_CR43","doi-asserted-by":"publisher","first-page":"108515","DOI":"10.1016\/j.clim.2020.108515","volume":"218","author":"J Damoiseaux","year":"2020","unstructured":"Damoiseaux J. The IL-2 - IL-2 receptor pathway in health and disease: the role of the soluble IL-2 receptor. Clin Immunol (Orlando Fla). 2020;218:108515. https:\/\/doi.org\/10.1016\/j.clim.2020.108515.","journal-title":"Clin Immunol (Orlando Fla)"},{"issue":"10","key":"3364_CR44","first-page":"662","volume":"16","author":"S Colafrancesco","year":"2014","unstructured":"Colafrancesco S, Priori R, Alessandri C, et al. The hyperferritinemic syndromes and CD163: a marker of macrophage activation. Isr Med Association Journal: IMAJ. 2014;16(10):662\u20133.","journal-title":"Isr Med Association Journal: IMAJ"},{"issue":"1","key":"3364_CR45","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4161\/15384047.2014.972765","volume":"16","author":"S Dilwali","year":"2015","unstructured":"Dilwali S, Roberts D, Stankovic KM. Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells. Cancer Biol Ther. 2015;16(1):170\u20135. https:\/\/doi.org\/10.4161\/15384047.2014.972765.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"3364_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ajhg.2009.06.003","volume":"85","author":"JM Schultz","year":"2009","unstructured":"Schultz JM, Khan SN, Ahmed ZM, et al. Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39. Am J Hum Genet. 2009;85(1):25\u201339. https:\/\/doi.org\/10.1016\/j.ajhg.2009.06.003.","journal-title":"Am J Hum Genet"},{"key":"3364_CR47","doi-asserted-by":"publisher","unstructured":"Morell RJ, Olszewski R, Tona R et al. Noncoding Microdeletion in Mouse Hgf disrupts neural Crest Migration into the stria Vascularis, reduces the endocochlear potential, and suggests the neuropathology for human nonsyndromic deafness DFNB39. 2020;40(15):2976\u201392. https:\/\/doi.org\/10.1523\/jneurosci.2278-19.2020","DOI":"10.1523\/jneurosci.2278-19.2020"},{"issue":"5","key":"3364_CR48","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/00016489.2016.1266508","volume":"137","author":"N Kudo","year":"2017","unstructured":"Kudo N, Matsubara A, Nishizawa H, Miura T. Immunohistological analysis of eotaxin and RANTES in the model animal of eosinophilic otitis media. Acta Otolaryngol. 2017;137(5):476\u201381. https:\/\/doi.org\/10.1080\/00016489.2016.1266508.","journal-title":"Acta Otolaryngol"},{"issue":"12","key":"3364_CR49","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/glia.22892","volume":"63","author":"B Parajuli","year":"2015","unstructured":"Parajuli B, Horiuchi H, Mizuno T, Takeuchi H, Suzumura A. CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia. 2015;63(12):2274\u201384. https:\/\/doi.org\/10.1002\/glia.22892.","journal-title":"Glia"},{"issue":"1","key":"3364_CR50","first-page":"1","volume":"11","author":"B Ham","year":"2016","unstructured":"Ham B, Fernandez MC, D\u2019Costa Z, Brodt P. The diverse roles of the TNF axis in cancer progression and metastasis. Trends cancer Res. 2016;11(1):1\u201327.","journal-title":"Trends cancer Res"},{"issue":"7","key":"3364_CR51","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1002\/eji.201041205","volume":"41","author":"R Hamano","year":"2011","unstructured":"Hamano R, Huang J, Yoshimura T, Oppenheim JJ, Chen X. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol. 2011;41(7):2010\u201320. https:\/\/doi.org\/10.1002\/eji.201041205.","journal-title":"Eur J Immunol"},{"issue":"3","key":"3364_CR52","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.immuni.2013.02.007","volume":"38","author":"M Sade-Feldman","year":"2013","unstructured":"Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M. Tumor necrosis factor-\u03b1 blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity. 2013;38(3):541\u201354. https:\/\/doi.org\/10.1016\/j.immuni.2013.02.007.","journal-title":"Immunity"},{"issue":"10","key":"3364_CR53","doi-asserted-by":"publisher","first-page":"6467","DOI":"10.4049\/jimmunol.180.10.6467","volume":"180","author":"X Chen","year":"2008","unstructured":"Chen X, Subleski JJ, Kopf H, Howard OM, M\u00e4nnel DN, Oppenheim JJ. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4\u2009+\u2009CD25\u2009+\u2009FoxP3\u2009+\u2009T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol (Baltimore Md: 1950). 2008;180(10):6467\u201371. https:\/\/doi.org\/10.4049\/jimmunol.180.10.6467.","journal-title":"J Immunol (Baltimore Md: 1950)"},{"issue":"11","key":"3364_CR54","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.molmed.2017.09.007","volume":"23","author":"\u00c9S Vanamee","year":"2017","unstructured":"Vanamee \u00c9S, Faustman DL. TNFR2: a Novel Target for Cancer Immunotherapy. Trends Mol Med. 2017;23(11):1037\u201346. https:\/\/doi.org\/10.1016\/j.molmed.2017.09.007.","journal-title":"Trends Mol Med"},{"issue":"14","key":"3364_CR55","doi-asserted-by":"publisher","first-page":"e33470","DOI":"10.1097\/md.0000000000033470","volume":"102","author":"Y Fu","year":"2023","unstructured":"Fu Y, Zhu Y, Guo L, Liu Y. Identification of key genes and immune infiltration based on weighted gene co-expression network analysis in vestibular schwannoma. Medicine. 2023;102(14):e33470. https:\/\/doi.org\/10.1097\/md.0000000000033470.","journal-title":"Medicine"},{"issue":"1","key":"3364_CR56","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3892\/ol.2016.5403","volume":"13","author":"T Zhao","year":"2017","unstructured":"Zhao T, Li H, Liu Z. Tumor necrosis factor receptor 2 promotes growth of colorectal cancer via the PI3K\/AKT signaling pathway. Oncol Lett. 2017;13(1):342\u20136. https:\/\/doi.org\/10.3892\/ol.2016.5403.","journal-title":"Oncol Lett"},{"issue":"52","key":"3364_CR57","doi-asserted-by":"publisher","first-page":"18200","DOI":"10.1073\/pnas.0405971102","volume":"101","author":"R Rong","year":"2004","unstructured":"Rong R, Tang X, Gutmann DH, Ye K. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci USA. 2004;101(52):18200\u20135. https:\/\/doi.org\/10.1073\/pnas.0405971102.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"3364_CR58","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/1541-7786.mcr-10-0210","volume":"9","author":"KE Hamilton","year":"2011","unstructured":"Hamilton KE, Simmons JG, Ding S, Van Landeghem L, Lund PK. Cytokine induction of tumor necrosis factor receptor 2 is mediated by STAT3 in colon cancer cells. Mol cancer Research: MCR. 2011;9(12):1718\u201331. https:\/\/doi.org\/10.1158\/1541-7786.mcr-10-0210.","journal-title":"Mol cancer Research: MCR"},{"issue":"5","key":"3364_CR59","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrd2488","volume":"7","author":"JA Winkles","year":"2008","unstructured":"Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discovery. 2008;7(5):411\u201325. https:\/\/doi.org\/10.1038\/nrd2488.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"3364_CR60","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1600-065X.2011.01054.x","volume":"244","author":"LC Burkly","year":"2011","unstructured":"Burkly LC, Michaelson JS, Zheng TS. TWEAK\/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev. 2011;244(1):99\u2013114. https:\/\/doi.org\/10.1111\/j.1600-065X.2011.01054.x.","journal-title":"Immunol Rev"},{"issue":"6","key":"3364_CR61","doi-asserted-by":"publisher","first-page":"101042831771462","DOI":"10.1177\/1010428317714624","volume":"39","author":"G Hu","year":"2017","unstructured":"Hu G, Zeng W, Xia Y. TWEAK\/Fn14 signaling in tumors. Tumour Biology: J Int Soc Oncodevelopmental Biology Med. 2017;39(6):1010428317714624. https:\/\/doi.org\/10.1177\/1010428317714624.","journal-title":"Tumour Biology: J Int Soc Oncodevelopmental Biology Med"},{"issue":"1","key":"3364_CR62","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1083\/jcb.200801010","volume":"182","author":"JE Vince","year":"2008","unstructured":"Vince JE, Chau D, Callus B, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol. 2008;182(1):171\u201384. https:\/\/doi.org\/10.1083\/jcb.200801010.","journal-title":"J Cell Biol"},{"key":"3364_CR63","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fneur.2019.00665","volume":"10","author":"A Warnecke","year":"2019","unstructured":"Warnecke A, Prenzler NK, Schmitt H, et al. Defining the Inflammatory Microenvironment in the Human Cochlea by Perilymph Analysis: toward Liquid Biopsy of the Cochlea. Front Neurol. 2019;10:665. https:\/\/doi.org\/10.3389\/fneur.2019.00665.","journal-title":"Front Neurol"},{"issue":"4","key":"3364_CR64","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/bph.12337","volume":"170","author":"H Wajant","year":"2013","unstructured":"Wajant H. The TWEAK-Fn14 system as a potential drug target. Br J Pharmacol. 2013;170(4):748\u201364. https:\/\/doi.org\/10.1111\/bph.12337.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"3364_CR65","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.molonc.2015.03.009","volume":"9","author":"S Dilwali","year":"2015","unstructured":"Dilwali S, Bri\u00ebt MC, Kao SY, et al. Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth. Mol Oncol. 2015;9(7):1359\u201370. https:\/\/doi.org\/10.1016\/j.molonc.2015.03.009.","journal-title":"Mol Oncol"},{"issue":"1","key":"3364_CR66","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1038\/s41598-018-23609-7","volume":"8","author":"JE Sagers","year":"2018","unstructured":"Sagers JE, Brown AS, Vasilijic S, et al. Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma. Sci Rep. 2018;8(1):5437. https:\/\/doi.org\/10.1038\/s41598-018-23609-7.","journal-title":"Sci Rep"},{"issue":"1","key":"3364_CR67","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40136-018-0186-4","volume":"6","author":"Y Ren","year":"2018","unstructured":"Ren Y, Stankovic KM. The role of Tumor necrosis factor alpha (TNF\u03b1)in hearing loss and vestibular Schwannomas. Curr Otorhinolaryngol Rep. 2018;6(1):15\u201323. https:\/\/doi.org\/10.1007\/s40136-018-0186-4.","journal-title":"Curr Otorhinolaryngol Rep"},{"key":"3364_CR68","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3389\/fneur.2019.00977","volume":"10","author":"LD Landegger","year":"2019","unstructured":"Landegger LD, Vasilijic S, Fujita T, et al. Cytokine levels in inner ear fluid of Young and aged mice as molecular biomarkers of noise-Induced hearing loss. Front Neurol. 2019;10:977. https:\/\/doi.org\/10.3389\/fneur.2019.00977.","journal-title":"Front Neurol"},{"key":"3364_CR69","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3389\/fneur.2019.01353","volume":"10","author":"S Katsumi","year":"2019","unstructured":"Katsumi S, Sahin MI, Lewis RM, Iyer JS, Landegger LD, Stankovic KM. Intracochlear Perfusion of Tumor Necrosis factor-alpha induces sensorineural hearing loss and synaptic degeneration in Guinea Pigs. Front Neurol. 2019;10:1353. https:\/\/doi.org\/10.3389\/fneur.2019.01353.","journal-title":"Front Neurol"},{"issue":"93","key":"3364_CR70","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4103\/nah.NAH_34_17","volume":"20","author":"LLM Marchiori","year":"2018","unstructured":"Marchiori LLM, Dias ACM, Gon\u00e7alvez AS, Poly-Frederico RC, Doi MY. Association between polymorphism of tumor necrosis factor alpha (tnf\u03b1) in the region\u2013\u2009308\u00a0g\/a with tinnitus in the elderly with a history of occupational noise exposure. Noise Health. 2018;20(93):37\u201341. https:\/\/doi.org\/10.4103\/nah.NAH_34_17.","journal-title":"Noise Health"},{"issue":"1","key":"3364_CR71","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12979-014-0018-4","volume":"11","author":"Y Uchida","year":"2014","unstructured":"Uchida Y, Sugiura S, Ueda H, Nakashima T, Ando F, Shimokata H. The association between hearing impairment and polymorphisms of genes encoding inflammatory mediators in Japanese aged population. Immun Ageing: I a. 2014;11(1):18. https:\/\/doi.org\/10.1186\/s12979-014-0018-4.","journal-title":"Immun Ageing: I a"},{"key":"3364_CR72","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3389\/fimmu.2017.01739","volume":"8","author":"L Frejo","year":"2017","unstructured":"Frejo L, Requena T, Okawa S, et al. Regulation of Fn14 receptor and NF-\u03baB underlies inflammation in Meniere\u2019s Disease. Front Immunol. 2017;8:1739. https:\/\/doi.org\/10.3389\/fimmu.2017.01739.","journal-title":"Front Immunol"},{"key":"3364_CR73","doi-asserted-by":"publisher","unstructured":"Nagy D, Ennis KA, Wei R, et al. Developmental synaptic regulator, TWEAK\/Fn14 signaling, is a determinant of synaptic function in models of stroke and neurodegeneration. Proc Natl Acad Sci USA. 2021;118(6). https:\/\/doi.org\/10.1073\/pnas.2001679118.","DOI":"10.1073\/pnas.2001679118"},{"key":"3364_CR74","doi-asserted-by":"publisher","unstructured":"Kandathil CK, Cunnane ME, McKenna MJ, Curtin HD, Stankovic KM. Correlation Between Aspirin Intake and Reduced Growth of Human Vestibular Schwannoma: Volumetric Analysis. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2016;37(9):1428\u201334. https:\/\/doi.org\/10.1097\/MAO.0000000000001180.","DOI":"10.1097\/MAO.0000000000001180"},{"issue":"3","key":"3364_CR75","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0194-5998(95)70101-X","volume":"113","author":"Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma)","year":"1995","unstructured":"Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC. Otolaryngology\u2013head and neck surgery. Official J Am Acad Otolaryngology-Head Neck Surg. 1995;113(3):179\u201380. https:\/\/doi.org\/10.1016\/S0194-5998(95)70101-X.","journal-title":"Official J Am Acad Otolaryngology-Head Neck Surg"},{"key":"3364_CR76","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fncel.2020.00191","volume":"14","author":"Y Ren","year":"2020","unstructured":"Ren Y, Hyakusoku H, Sagers JE, Landegger LD, Welling DB, Stankovic KM. MMP-14 (MT1-MMP) is a biomarker of Surgical Outcome and a potential mediator of hearing loss in patients with vestibular Schwannomas. Front Cell Neurosci. 2020;14:191. https:\/\/doi.org\/10.3389\/fncel.2020.00191.","journal-title":"Front Cell Neurosci"},{"key":"3364_CR77","doi-asserted-by":"publisher","unstructured":"Landegger LD, Sagers JE, Dilwali S, Fujita T, Sahin MI, Stankovic KM. A unified Methodological Framework for Vestibular Schwannoma Research. J Visualized Experiments: JoVE. 2017(124). https:\/\/doi.org\/10.3791\/55827","DOI":"10.3791\/55827"},{"issue":"9","key":"3364_CR78","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1021\/pr200346q","volume":"10","author":"AC Lysaght","year":"2011","unstructured":"Lysaght AC, Kao SY, Paulo JA, Merchant SN, Steen H, Stankovic KM. Proteome of human perilymph. J Proteome Res. 2011;10(9):3845\u201351. https:\/\/doi.org\/10.1021\/pr200346q.","journal-title":"J Proteome Res"},{"issue":"6","key":"3364_CR79","doi-asserted-by":"publisher","first-page":"e0218292","DOI":"10.1371\/journal.pone.0218292","volume":"14","author":"HC Lin","year":"2019","unstructured":"Lin HC, Ren Y, Lysaght AC, Kao SY, Stankovic KM. Proteome of normal human perilymph and perilymph from people with disabling vertigo. PLoS ONE. 2019;14(6):e0218292. https:\/\/doi.org\/10.1371\/journal.pone.0218292.","journal-title":"PLoS ONE"},{"issue":"9","key":"3364_CR80","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","volume":"70","author":"HK Wong","year":"2010","unstructured":"Wong HK, Lahdenranta J, Kamoun WS, et al. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res. 2010;70(9):3483\u201393. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3107.","journal-title":"Cancer Res"},{"issue":"13","key":"3364_CR81","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1523\/jneurosci.4923-13.2014","volume":"34","author":"MC Liberman","year":"2014","unstructured":"Liberman MC, Liberman LD, Maison SF. Efferent feedback slows cochlear aging. J Neuroscience: Official J Soc Neurosci. 2014;34(13):4599\u2013607. https:\/\/doi.org\/10.1523\/jneurosci.4923-13.2014.","journal-title":"J Neuroscience: Official J Soc Neurosci"},{"issue":"9","key":"3364_CR82","doi-asserted-by":"publisher","first-page":"E2077","DOI":"10.1073\/pnas.1719966115","volume":"115","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Liu P, Zhang N, et al. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci USA. 2018;115(9):E2077\u201384. https:\/\/doi.org\/10.1073\/pnas.1719966115.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"3364_CR83","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10162-014-0476-6","volume":"15","author":"K Hirose","year":"2014","unstructured":"Hirose K, Hartsock JJ, Johnson S, Santi P, Salt AN. Systemic lipopolysaccharide compromises the blood-labyrinth barrier and increases entry of serum fluorescein into the perilymph. J Association Res Otolaryngology: JARO. 2014;15(5):707\u201319. https:\/\/doi.org\/10.1007\/s10162-014-0476-6.","journal-title":"J Association Res Otolaryngology: JARO"},{"issue":"4","key":"3364_CR84","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nprot.2009.28","volume":"4","author":"BA Tannous","year":"2009","unstructured":"Tannous BA. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat Protoc. 2009;4(4):582\u201391. https:\/\/doi.org\/10.1038\/nprot.2009.28.","journal-title":"Nat Protoc"},{"issue":"4","key":"3364_CR85","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/s0895-4356(00)00314-0","volume":"54","author":"R Bender","year":"2001","unstructured":"Bender R, Lange S. Adjusting for multiple testing\u2013when and how? J Clin Epidemiol. 2001;54(4):343\u20139. https:\/\/doi.org\/10.1016\/s0895-4356(00)00314-0.","journal-title":"J Clin Epidemiol"}],"updated-by":[{"DOI":"10.1186\/s12974-025-03484-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03364-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-025-03364-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03364-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T02:32:23Z","timestamp":1754361143000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-025-03364-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3364"],"URL":"https:\/\/doi.org\/10.1186\/s12974-025-03364-z","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12974-025-03484-6","URL":"https:\/\/doi.org\/10.1186\/s12974-025-03484-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human specimens and data collection were approved by the Institutional Review Board of the Massachusetts General Hospital (MGH) and Massachusetts Eye and Ear (MEE) (IRB protocol #14\u2013148\u00a0H), as well as Stanford (IRB protocol # 60363). All participants provided written informed consent prior to participation. All animal procedures were performed following the guidelines of the Public Health Service Policy on Humane Care of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of MGH and MEE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}